Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13270644 | 0.81 | TAAR1 (0.45) | GAAIDO1PLA2G1BATG4BEGFR | |
| SCHEMBL1965925 | 0.80 | IDO1 (0.45) | IDO1EGFRERBB2SMN1; SMN2LMNA | |
| SCHEMBL838150 | 0.80 | CA2 (0.46) | IDO1ALDH1A1RAB9ACTBP2LMNA | |
| SCHEMBL834044 | 0.78 | MEN1 (0.36) | IDO1KMT2A | |
| SCHEMBL1580990 | 0.78 | IDO1 (0.44) | GAAIDO1EGFRERBB2ALDH1A1 | |
| SCHEMBL23586287 | 0.78 | ALDH1A1 (0.42) | IDO1ALDH1A1TDP1KMT2ALOXL2 | |
| SCHEMBL480288 | 0.78 | CYP3A4 (0.35) | IDO1KMT2A | |
| SCHEMBL641405 | 0.78 | IDO1 (0.44) | IDO1EGFRERBB2ALDH1A1RAB9A | |
| SCHEMBL836580 | 0.78 | MAPK8 (0.39) | IDO1ALDH1A1HTT | |
| SCHEMBL562722 | 0.78 | HDAC1 (0.54) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-118613483-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| CN-107108638-A | Piperidyl PyrazolopyrimidinonecGMP and application thereof | 拜耳制药股份公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-105189511-B | Inhibitors of human immunodeficiency virus replication | 百时美施贵宝公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| CN-101282976-A | Xanthine derivatives as selective HM74A agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282977-A | Xanthine derivatives as selective hm74a agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101218231-A | Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1896464-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| CN-101001846-A | Novel alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-07-18 | — | — | CN | disclosed |
| WO-2006129199-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | GAA 310/4885IDO1 721/4885PLA2G1B 4322/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | GAA 426/4885IDO1 821/4885PLA2G1B 4345/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | GAA 310/4885IDO1 721/4885PLA2G1B 4322/4885 |
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GAA 225/4885IDO1 1751/4885PLA2G1B 4009/4885 |
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | GAA 1190/4885IDO1 1195/4885PLA2G1B 563/4885 |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | PAH, TST, MPST | GAA 76/4885IDO1 3672/4885PLA2G1B 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.